Geron Corporation (GERN) was Reiterated by FBR Capital to “Outperform” while Lowering the Price Target of the company shares to $ 5 from a previous price target of $6 . FBR Capital advised their investors in a research report released on Sep 13, 2016.
On the company’s financial health, Geron Corporation reported $-0.05 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.06. The company had revenue of $.21 million for the quarter, compared to analysts expectations of $.38 million. The company’s revenue was down -15.9 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.06 EPS.
Geron Corporation closed down -0.56 points or -19.58% at $2.3 with 12,942,290 shares getting traded on Monday. Post opening the session at $2.12, the shares hit an intraday low of $2.06 and an intraday high of $2.45 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jun 1, 2015, Olivia Kyusuk Bloom (EVP, Chief Financial Officer) sold 2,380 shares at $3.84 per share price. According to the SEC, on Jun 1, 2015, Melissa Kelly Behrs (EVP BD and Port&Alliance Mgmt) sold 2,380 shares at $3.84 per share price. On Mar 19, 2015, Thomas Hofstaetter (director) sold 70,000 shares at $4.10 per share price, according to the Form-4 filing with the securities and exchange commission.
Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor imetelstat in hematologic myeloid malignancies. The Company operates in one segment the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells including malignant progenitor cells to maintain telomere length which provides a capacity for limitless uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR) which binds to the telomere and a catalytic subunit (hTERT) with reverse transcriptase activity which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.